RBFF

General

Prediction Of Molecular Mutations In Diffuse Low-Grade Gliomas

Di: Amelia

Shboul et al. achieved significant results in the non-invasive prediction of molecular mutations in low-grade gliomas using ML models developed for this purpose, which showed

These molecular characteristics can be used to refine glioma classification, to improve prediction of patient outcomes, and to guide individualized treatment. Lower-grade gliomas refer to diffuse low-grade and intermediate-grade gliomas lower grade glioma Conventional MR (World Health Organization grades II and III) [1], which have highly variable clinical behaviour This study investigates a data-centric machine learning approach to determine their potential benefits in predicting glioma grades.

Perspectives on IDH Mutation in Diffuse Gliomas: Trends in Cancer

Background Intratumor heterogeneity (ITH) is a key biological characteristic of gliomas. This study aimed to characterize ITH in adult-type diffuse gliomas and assess the

Advances in the molecular genetics of gliomas

GlioMT is trained on multiparametric MRI data from an institutional set of 1053 patients with adult-type diffuse gliomas to predict the IDH mutation status, 1p/19q codeletion Introduction It is useful to know the molecular subtype of lower-grade gliomas (LGG) precursor cells and Diffuse gliomas when deciding on a treatment strategy. This study aims to diagnose this preoperatively. Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical

And seizure duration of over 6 years was defined as a predictor of postoperative seizures in patients with diffuse low-grade-glioma-related epilepsy after complete tumor

Rapidly emerging and evolving molecular classifications of gliomas have influenced treatment paradigms. Importantly, low-grade gliomas can be classified on the basis of IDH Clinical relevance Tumor oxygenation parameters derived from dynamic susceptibility contrast (DSC) perfusion imaging may assist noninvasive prediction of IDH

On the other hand, in pediatric-type diffuse low-grade gliomas and circumscribed astrocytic gliomas, molecular diagnostics may be extremely complicated at a glance in the Conclusions Radiomics based on TTP images extracted from dynamic [18 F]FET PET can predict the TERTp-mutation status of IDH-wildtype diffuse astrocytic high-grade

In glioma, IDH mutations are recognised in >80% of World Health Organisation (WHO) grade II/III cases. 7 In WHO grade IV glioblastoma (GBM), IDH mutations are also Objectives To develop a gadolinium-free MRI-based diagnosis prediction decision tree (DPDT) for adult-type diffuse gliomas and to assess the added value of gadolinium-based Gliomas are traditionally divided into histological grades I-IV. Recent advances in diagnostics and understanding of glioma molecular background have revolutionized its

However, patients may also be asymptomatic, without evident abnormalities on neurologic examination. D iagnosis Diagnosis of LGGs is made through a combination of A tumor that has mutations in FGFRs and/or BRAF and morphologically resembles a diffuse glioma, this preoperatively according to the new WHO CNS5 classification, qualifies as diffuse low grade glioma, Purpose Adult patients with diffuse lower-grade gliomas (dLGG) show heterogeneous survival outcomes, complicating postoperative treatment planning. Treating all

Lower-grade gliomas (LGGs) are defined as World Health Organization (WHO) grades II and III gliomas, including diffuse low-grade and intermediate-grade gliomas,

Abstract The identification of distinct genetic and epigenetic profiles in different types of gliomas has revealed novel diagnostic, prognostic, and predictive molecular

Gliomas can be classified into five molecular groups based on the status of IDH mutation, 1p/19q codeletion, and TERT promoter mutation, whereas they need to be obtained Molecular features in low-grade gliomas There have been significant advances in the knowledge about the molecular biology of gliomas along with the development of a series of biomarkers

In high-grade glioma glioblastoma and low-grade glioma oligodendroglioma, mutations in pTERT can be detected with a high probability. According to the cIMPACT-NOW update, mutations in Introduction Diffuse lower-grade glioma [LGG, World Health Organization (WHO) grades II and III] is a primary brain tumor that originates from glial or precursor cells and Diffuse gliomas in children are divided into clinically indolent low-grade tumours and high-grade tumours with aggressive behaviour, with histone 3 K27-altered diffuse midline

Abstract Molecular subtyping and grading of adult-type diffuse gliomas are essential for treatment decisions and patient prognosis. We introduce GlioMT, an interpretable Of which have highly variable clinical note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical

Background The relationship between molecular phenotype and prognosis in high-grade gliomas (WHO III and IV, HGG) treated with radiotherapy and chemotherapy is not fully Objective: Telomerase reverse transcriptase (TERT) promoter mutation status in gliomas is a key determinant of treatment strategy and Purpose Isocitrate dehydrogenase (IDH) and 1p19q codeletion status are importantin providing prognostic information as well as prediction of treatment response in

Understanding the molecular and pathological features of paediatric low-grade glioma (pLGG) is crucial to develop targeted therapies. Here, the authors perform a

Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma Conventional MR Of note, several recent studies have shown that some low-grade IDH-wild-type astrocytoma lacking both the molecular glioblastoma signature and genetic alterations typical Gliomas, the most prevalent type of primary brain tumors, require precise molecular characterization for effective diagnosis and treatment. Despite advancements in

Background In lower-grade gliomas (LrGGs, histological grades 2–3), there exist a minority of high-risk molecular subtypes with malignant transformation potential, associated

The molecular profiling of gliomas for isocitrate dehydrogenase (IDH) mutations currently relies on resected tumor samples, highlighting the need for non-invasive, preoperative